Termination of clozapine treatment due to medical reasons: When is it warranted and how can it be avoided?

Journal of Clinical Psychiatry

Volumn 74, Issue 6, 2013, Pages 603-613

  Nielsen, Jimmi ^a   Correll, Christoph U ^b,c   Manu, Peter ^b,c,d   Kane, John M ^b,c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; CLOZAPINE; GABAPENTIN; LAMOTRIGINE; LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; VALPROIC ACID;

AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOMYOPATHY; CONSTIPATION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG DOSE REDUCTION; DRUG RECHALLENGE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; EOSINOPHILIA; EPILEPSY; FAINTNESS; FEVER; HEART ATRIUM FLUTTER; HEART REPOLARIZATION; HUMAN; HYPERTENSION; ILEUS; LEUKOCYTOSIS; METABOLIC SYNDROME X; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NONKETOTIC DIABETIC COMA; OBESITY; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PRIORITY JOURNAL; QT PROLONGATION; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; T WAVE INVERSION; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; VENOUS THROMBOEMBOLISM; WEIGHT CONTROL; WEIGHT GAIN;

EID: 84879577182     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12r08064     Document Type: Article

References (114)

1. Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol. 2012;32(5):678-683. doi:10.1097/JCP. 0b013e318267b3cd PubMed
2. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796. doi:10.101/archpsyc. 198.0180301301 PubMed
3. Azorin JM, Spiegel R, Remington G, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001;158(8):1305-1313. doi:10.176/api.ajp.158.8. 1305 PubMed
4. Conley RR, Kelly DL, Richardson CM, et al. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a doubleblind crossover study. J Clin Psychopharmacol. 2003;23(6):668-671. doi:10.1097/01.jcp.096246.29231.73 PubMed
5. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373(9657):31-41. doi:10.1016/S0140-6736(08)61764-X PubMed
6. Meltzer HY, Alphs L, Green AI, et al; International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91. doi:10.101/archpsyc.60.1.82 PubMed
7. Chengappa KN, Vasile J, Levine J, et al. Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophr Res. 2002; 53(1-2):1-6. doi:10.1016/S0920-964(0)0175-4 PubMed
8. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry. 2003;64(4):451-458. doi:10.408/JCP.v64n0416 PubMed
9. Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord. 2012;14(8):863-869. doi:10.1/bdi.12018 PubMed
10. Pollack S, Woerner MG, Howard A, et al. Clozapine reduces rehospitalization among schizophrenia patients. Psychopharmacol Bull. 1998;34(1):89-92. PubMed
11. Angermeyer MC, Löffler W, Müller P, et al. Patients' and relatives' assessment of clozapine treatment. Psychol Med. 2001;31(3):509-517. doi:10.1017/S0329170103749 PubMed
12. Merrill DB, Ahmari SE, Bradford JM, et al. Myocarditis during clozapine treatment. Am J Psychiatry. 2006;163(2):204-208. doi:10.176/api.ajp.163.2.204 PubMed
13. Taylor DM, Douglas-Hall P, Olofinjana B, et al. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. Br J Psychiatry. 2009;194(2):165-167. doi:10.192/bjp.bp.108.051979 PubMed
14. Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull. 2012;38(3):592-598. doi:10.1093/schbul/sbq137 PubMed
15. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101(3):277-288. doi:10.1016/S0165-1781(01)0234-7 PubMed
16. Seppälä N, Kovio C, Leinonen E. Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal. CNS Drugs. 2005;19(12):1049-1055. doi:10.2165/023210-20519120-06 PubMed
17. Krivoy A, Malka L, Fischel T, et al. Predictors of clozapine discontinuation in patients with schizophrenia. Int Clin Psychopharmacol. 2011;26(6):311-315. doi:10.1097/YIC.0b013e32834ab34c PubMed
18. Pai NB, Vella SC. Reason for clozapine cessation. Acta Psychiatr Scand. 2012; 125(1):39-44. doi:10.1/j.160-047.201.0176.x PubMed
19. Whiskey E, Wykes T, Duncan-McConnell D, et al. Continuation of clozapine treatment: practice makes perfect. Psychiatr Bull. 2003;27(6):211-213. doi:10.192/pb.27.6.21
20. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry. 1999;175(6):576-580. doi:10.192/bjp.175.6.576 PubMed
21. Moeller FG, Chen YW, Steinberg JL, et al. Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Ann Clin Psychiatry. 1995;7(4):167-173. doi:10.3109/1040123950914962 PubMed
22. Nielsen J, Damkier P, Lublin H, et al. Optimizing clozapine treatment. Acta Psychiatr Scand. 2011;123(6):411-422. doi:10.1/j.160-047.201.01710.x PubMed
23. Nielsen J, Dahm M, Lublin H, et al. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24(7):965-971. doi:10.17/0269810810320 PubMed
24. Manu P, Sarpal D, Muir O, et al. When can patients with potentially lifethreatening adverse effects be rechallenged with clozapine? a systematic review of the published literature. Schizophr Res. 2012;134(2-3):180-186. doi:10.1016/j.schres.201.10.014 PubMed
25. Lindström LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand. 1988;77(5):524-529. doi:10.1/j.160-047. 198.tb05164.x PubMed
26. Nielsen J, Graff C, Kanters JK, et al. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs. 2011;25(6):473-490. doi:10.2165/158780-0-0 PubMed
27. Nielsen J, Andersen MP, Graff C, et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand. 2010;121(5):385-388. doi:10.1/j.160-047.209. 01534.x PubMed
28. Kang UG, Kwon JS, Ahn YM, et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry. 2000;61(6):441-446. doi:10.408/JCP.v61n0609 PubMed
29. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol. 2005;25(1):32-41. doi:10.1097/01.jcp.0150217. 5143.9f PubMed
30. Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011;45(6):458-465. doi:10.3109/048674.201. 572852 PubMed
31. Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophr Res. 2011;128(1-3):161-165. doi:10.1016/j.schres. 201.01.017 PubMed
32. Bray A, Reid R. Successful clozapine rechallenge after acute myocarditis. Aust N Z J Psychiatry. 2011;45(1):90. doi:10.3109/048674.2010.5365 PubMed
33. Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. Observations from 8 cases of clozapine rechallenge after development of myocarditis. J Clin Psychiatry. 2012;73(2):252-254. doi:10.408/JCP.1l07467 PubMed
34. Testani M Jr. Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry. 1994;55(11):497-498. PubMed
35. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 2008;7(5):451-458. doi:10.1016/S1474-42(08)708-7 PubMed
36. Stryjer R, Timinsky I, Reznik I, et al. Beta-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: a retrospective study. Clin Neuropharmacol. 2009;32(5):290-292. doi:10.1097/WNF.0b013e3181a620b2 PubMed
37. Marinkovic D, Timotijevic I, Babinski T, et al. The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18(3):537-544. doi:10.1016/0278-5846(94)9010-8 PubMed
38. Rakovec P. Treatment of inappropriate sinus tachycardia with ivabradine. Wien Klin Wochenschr. 2009;121(21-22):715-718. doi:10.107/s0508-09-1265-9 PubMed
39. Ketch J, Herd A, Ludwig L. ST segment elevations without myocardial infarction in a patient on clozapine. Am J Emerg Med. 1996;14(1):111-112. doi:10.1016/S0735-6757(96)9036-4 PubMed
40. Low RA Jr, Fuller MA, Popli A. Clozapine induced atrial fibrillation. J Clin Psychopharmacol. 1998;18(2):170. doi:10.1097/04714-198040-010 PubMed
41. Amital D, Gross R, Amital H, et al. Coexistence of eosinophilia and agranulocytosis in a clozapine-treated patient. Br J Psychiatry. 1997;170:194. PubMed
42. Fong SY, Au Yeung KL, Tosh JM, et al. Clozapine-induced toxic hepatitis with skin rash. J Psychopharmacol. 2005;19(1):107. doi:10.17/02698105047287 PubMed
43. Ames D, Wirshing WC, Baker RW, et al. Predictive value of eosinophilia for neutropenia during clozapine treatment. J Clin Psychiatry. 1996;57(12):579-581. doi:10.408/JCP.v57n1205 PubMed
44. Lucht MJ, Rietschel M. Clozapine-induced eosinophilia: subsequent neutropenia and corresponding allergic mechanisms. J Clin Psychiatry. 1998;59(4):195-197. doi:10.408/JCP.v59n0409c PubMed
45. Duggal HS, Singh I. Psychotropic drug-induced neutropenia. Drugs Today (Barc). 2005;41(8):517-526. doi:10.1358/dot.205.41.8.893629 PubMed
46. Duggal HS, Singh I. Re: late-onset neutropenia with clozapine [letter]. Can J Psychiatry. 2006;51(2):125. Author reply: 125-126. PubMed
47. Small JG, Weber MC, Klapper MH, et al. Rechallenge of late-onset neutropenia with clozapine. J Clin Psychopharmacol. 2005;25(2):185-186. doi:10.1097/01.jcp.015831.72154.bc PubMed
48. Thompson A, Girishchandra B, Castle D, et al. Late onset neutropenia with clozapine. Can J Psychiatry. 2004;49(9):647-648. PubMed
49. Tamam L, Kulan E, Ozpoyraz N. Late onset neutropenia during clozapine treatment. Psychiatry Clin Neurosci. 2001;55(5):547-548. doi:10.1046/j.140-1819. 201.904(1).x PubMed
50. Hummer M, Kurz M, Barnas C, et al. Transient neutropenia induced by clozapine. Psychopharmacol Bull. 1992;28(3):287-290. PubMed
51. McKee JR, Wall T, Owensby J. Impact of complete blood count sampling time change on white blood cell and absolute neutrophil count values in clozapine recipients. Clin Schizophr Relat Psychoses. 2011;5(1):26-32. doi:10.371/CSRP.5.1.4 PubMed
52. Esposito D, Chouinard G, Hardy P, et al. Successful initiation of clozapine treatment despite morning pseudoneutropenia. Int J Neuropsychopharmacol. 2006;9(4):489-491. doi:10.1017/S1461457050605X PubMed
53. Rajagopal S. Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J. 2005;81(959):545-546. doi:10.136/pgmj.204.03161 PubMed
54. Spencer BW, Williams HR, Gee SH, et al. Granulocyte colony stimulating factor (G-CSF) can allow treatment with clozapine in a patient with severe benign ethnic neutropaenia (BEN): a case report. J Psychopharmacol. 2012;26(9):1280-1282. doi:10.17/0269812450782 PubMed
55. Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs. 2007;21(1):25-35. doi:10.2165/023210-20721010-03 PubMed
56. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol. 2008;23(suppl 1):27-41. doi:10.102/hup.917 PubMed
57. Brunoni AR, Kobuti Ferreira LR, Gallucci-Neto J, et al. Lithium as a treatment of clozapine-induced neutropenia: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):2006-2007. doi:10.1016/j.pnpbp. 208.09.05 PubMed
58. Kutscher EC, Robbins GP, Kennedy WK, et al. Clozapine-induced leukopenia successfully treated with lithium. Am J Health Syst Pharm. 2007;64(19):2027- 2031. doi:10.2146/ajhp060319 PubMed
59. Hagg S, Rosenius S, Spigset O. Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. Int Clin Psychopharmacol. 2003;18(3):173-174. doi:10.1097/01.yic.06280.7434.6c PubMed
60. Schulte PF. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother. 2006;40(4):683-688. doi:10.1345/aph.1G396 PubMed
61. Nielsen J, Thode D, Stenager E, et al. Hematological clozapine monitoring with a point-of-care device: a randomized cross-over trial. Eur Neuropsychopharmacol. 2012;22(6):401-405. doi:10.1016/j.euroneuro.201.10.01 PubMed
62. Tharyan P. Is monitoring of platelets necessary during clozapine therapy? Indian J Psychiatry. 1999;41(3):263-264. PubMed
63. Mahendran R. Leukopenia and thrombocytopenia induced by clozapine. Hong Kong J Psychiatry. 2002;12(3):19-20.
64. Lambertenghi Deliliers G. Blood dyscrasias in clozapine-treated patients in Italy. Haematologica. 2000;85(3):233-237. PubMed
65. Focosi D, Azzarà A, Kast RE, et al. Lithium and hematology: established and proposed uses. J Leukoc Biol. 2009;85(1):20-28. doi:10.189/jlb.060838 PubMed
66. Hampson ME. Clozapine-induced thrombocytosis. Br J Psychiatry. 2000;176(4):400. doi:10.192/bjp.176.4.40-a PubMed
67. Sopko MA, Caley CF. Chronic leukocytosis associated with clozapine treatment. Clin Schizophr Relat Psychoses. 2010;4(2):141-144. doi:10.371/CSRP.4.2.6 PubMed
68. Madhusoodanan S, Cuni L, Brenner R, et al. Chronic leukocytosis associated with clozapine: a case series. J Clin Psychiatry. 2007;68(3):484-488. doi:10.408/JCP.v68n0320b PubMed
69. Popli A, Pies R. Clozapine and leukocytosis. J Clin Psychopharmacol. 1995;15(4):286-287. doi:10.1097/04714-195080-010 PubMed
70. Nielsen J, Boysen A. Clozapine treatment associated with increased risk of acute myeloid leukemia (AML). Schizophr Res. 2010;123(2-3):270-272. doi:10.1016/j.schres.2010.08.035 PubMed
71. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126. doi:10.1038/nrendo.201.156 PubMed
72. Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97-107. doi:10.1016/j.molmed.2010.10.010 PubMed
73. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012;140(1-3):159-168. doi:10.1016/j.schres.2012.03.017 PubMed
74. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology. 2010;35(7):1520-1530. doi:10.1038/np.2010.21 PubMed
75. Gallego JA, Nielsen J, De Hert M, et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527-542. doi:10.1517/1474038.2012.683523 PubMed
76. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology. 2010;35(9):1997-2004. doi:10.1038/np.2010.78 PubMed
77. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66(9):1116-1121. doi:10.408/JCP.v6n0905 PubMed
78. Cohen D. Atypical antipsychotics and new onset diabetes mellitus: an overview of the literature. Pharmacopsychiatry. 2004;37(1):1-11. doi:10.105/s-204-815468 PubMed
79. Cohen D, Correll CU. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. J Clin Psychiatry. 2009;70(5):765-766. doi:10.408/JCP.09ac0525 PubMed
80. Raja M. Clozapine safety, 35 years later. Curr Drug Saf. 2011;6(3):164-184. doi:10.2174/1574861797579230 PubMed
81. Henderson DC, Cagliero E, Copeland PM, et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry. 2007;68(4):533-541. doi:10.408/JCP.v68n0407 PubMed
82. Lowe CM, Grube RR, Scates AC. Characterization and clinical management of clozapine-induced fever. Ann Pharmacother. 2007;41(10):1700-1704. doi:10.1345/aph.1K126 PubMed
83. Tham JC, Dickson RA. Clozapine-induced fevers and 1-year clozapine discontinuation rate. J Clin Psychiatry. 2002;63(10):880-884. doi:10.408/JCP.v63n105 PubMed
84. Martin A. Acute pancreatitis associated with clozapine use. Am J Psychiatry. 1992;149(5):714. PubMed
85. Catalano G, Catalano MC, Frankel Wetter RL. Clozapine induced polyserositis. Clin Neuropharmacol. 1997;20(4):352-356. doi:10.1097/02826- 197080-07 PubMed
86. Friedberg JW, Frankenburg FR, Burk J, et al. Clozapine-caused eosinophilic colitis. Ann Clin Psychiatry. 1995;7(2):97-98. doi:10.3109/ 10401239509149034 PubMed
87. Nielsen J, Foldager L, Meyer JM. Increased use of antibiotics in patients treated with clozapine. Eur Neuropsychopharmacol. 2009;19(7):483-486. doi:10.1016/j.euroneuro.209.03.02 PubMed
88. Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatr Scand. 2005;112(3):238-240. Discussion: 240. doi:10.1/j.160-047.205.0578.x PubMed
89. Baciewicz AM, Chandra R, Whelan P. Clozapine-associated neuroleptic malignant syndrome. Ann Intern Med. 2002;137(5 pt 1):374. PubMed
90. Jönsson AK, Spigset O, Hägg S. Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management. CNS Drugs. 2012;26(8):649-662. doi:10.2165/163920-0-0 PubMed
91. Rondla S, Crane S. A case of clozapine-induced paralytic ileus. Emerg Med J. 2007;24(2):e12. doi:10.136/emj.206.042630 PubMed
92. Palmer SE, McLean RM, Ellis PM, et al. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69(5):759-768. doi:10.408/JCP.v69n0509 PubMed
93. Fitzsimons J, Berk M, Lambert T, et al. A review of clozapine safety. Expert Opin Drug Saf. 2005;4(4):731-744. doi:10.1517/1474038.4.4.731 PubMed
94. Flanagan RJ, Ball RY. Gastrointestinal hypomotility: an under-recognised life-threatening adverse effect of clozapine. Forensic Sci Int. 2011;206(1-3):e31-e36. doi:10.1016/j.forscint.2010.07.021 PubMed
95. Macfarlane B, Davies S, Mannan K, et al. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology. 1997;112(5):1707-1709. doi:10.1016/S016- 5085(97)7054-4 PubMed
96. Thatcher GW, Cates M, Bair B. Clozapine-induced toxic hepatitis. Am J Psychiatry. 1995;152(2):296-297. PubMed
97. Luo D, McColl P, Walmsley R. Acute onset of ascites with clozapineinduced hepatitis. Intern Med J. 2007;37(3):204-205. doi:10.1/j.145-594.206.0130.x PubMed
98. Hummer M, Kurz M, Kurzthaler I, et al. Hepatotoxicity of clozapine. J Clin Psychopharmacol. 1997;17(4):314-317. doi:10.1097/04714-197080-012 PubMed
99. Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol. 2011;7(7):875-890. doi:10.1517/1742525.201.57415 PubMed
100. Berk M, Fitzsimons J, Lambert T, et al. Monitoring the safe use of clozapine: a consensus view from Victoria, Australia. CNS Drugs. 2007;21(2):117-127. doi:10.2165/023210-20721020-03 PubMed
101. Markowitz JS, Grinberg R, Jackson C. Marked liver enzyme elevations with clozapine. J Clin Psychopharmacol. 1997;17(1):70-71. doi:10.1097/04714-197020- 025 PubMed
102. Eggert AE, Crismon ML, Dorson PG, et al. Clozapine rechallenge after marked liver enzyme elevation. J Clin Psychopharmacol. 1994;14(6):425-426. doi:10.1097/04714-194120-010 PubMed
103. Erdogan A, Kocabasoglu N, Yalug I, et al. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med. 2004;34(1):83-89. doi:10.2190/4WA-WXF7-3UHA- FDV1 PubMed
104. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology. 1991;41(3):369-371. doi:10.1212/WNL.41.3.369 PubMed
105. Freudenreich O, Weiner RD, McEvoy JP. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry. 1997;42(2):132-137. doi:10.1016/S06-323(96)0298-3 PubMed
106. Wong J, Delva N. Clozapine-induced seizures: recognition and treatment. Can J Psychiatry. 2007;52(7):457-463. PubMed
107. Muzyk A, Gala G, Kahn DA. Use of lamotrigine in a patient with a clozapine-related seizure. J Psychiatr Pract. 2010;16(2):125-128. doi:10.1097/01.pra.036974.18274.e2 PubMed
108. Usiskin SI, Nicolson R, Lenane M, et al. Gabapentin prophylaxis of clozapine-induced seizures. Am J Psychiatry. 2000;157(3):482-483. doi:10.176/api.ajp.157.3.482 PubMed
109. Jarbin H, Johansson BA, Lundgren J. Clozapine and therapy-refractory epileptic seizures. Eur Child Adolesc Psychiatry. 2001;10(3):209-210. doi:10.107/s0787017029 PubMed
110. Meyer JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol. 2001;21(6):569-574. doi:10.1097/04714-20120-05 PubMed
111. Haack MJ, Bak ML, Beurskens R, et al. Toxic rise of clozapine plasma concentrations in relation to inflammation. Eur Neuropsychopharmacol. 2003;13(5):381-385. doi:10.1016/S0924-97X(03)042-7 PubMed
112. Jecel J, Michel TM, Gutknecht L, et al. Toxic clozapine serum levels during acute urinary tract infection: a case report. Eur J Clin Pharmacol. 2005; 60(12):909-910. doi:10.107/s028-04-0867-4 PubMed
113. Sayin A, Cosar B. Prolongation of clozapine-induced leukopenia with olanzapine treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(5):958-959. doi:10.1016/j.pnpbp.205.1.032 PubMed
114. Tollefson GD, Birkett MA, Kiesler GM, et al; The Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52-63. doi:10.1016/S06-323(0)01026-X PubMed